Tipepidine in children with Autism Spectrum Disorder : a 4-week, open-label, preliminary study
Not Applicable
- Conditions
- Autism Spectrum Disorder
- Registration Number
- JPRN-UMIN000028350
- Lead Sponsor
- Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with a previous hypersensitivity to Tipepidine Hibenzate. 2.Patients treated with typical antipsychotics and selective norepinephrine reuptake inhibitor (NRI) except atomoxetine and stimulants except methylphenidate. 3.Pregnant or breast-feeding women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) [Time Frame: Changes from baseline in CY-BOCS at 4-weeks ]
- Secondary Outcome Measures
Name Time Method Repetitive Behavior Scale-Revised(RBS-R), Clinical Global Impression of Change(CGI-C), Vineland Adaptive Behavior Scales Second Edition(Vineland-II) the level of plasma glutamic acid,pro-BDNF,mature-BDNF,MMP-9,oxytocin [Time Frame:Change between baseline scores and 4-weeks]